3.90

0.78% 0.03

After Hours: 3.98 0.08 +2.05%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $3.90, with a volume of 2.85M. It is up +0.78% in the last 24 hours and up +23.03% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$3.87

Open:

$3.88

24h Volume:

2.85M

Relative Volume:

1.04

Market Cap:

$431.21M

Revenue:

$34.86M

Net Income/Loss:

$-103.80M

P/E Ratio:

-3.2928

EPS:

-1.1844

Net Cash Flow:

$-96.02M

1W Performance:

+1.30%

1M Performance:

+23.03%

6M Performance:

+57.89%

1Y Performance:

+140.74%

1-Day Range:

$3.84

$4.245

1-Week Range:

$3.44

$4.245

52-Week Range:

$1.36

$4.5981

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1109)

Industry

Biotechnology (621)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	3.90	427.90M	34.86M	-103.80M	-96.02M	-1.1844
VRTX Vertex Pharmaceuticals Inc	444.93	112.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	612.14	64.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	893.52	55.90B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.85	38.64B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	153.87	31.73B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

Jun 11, 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 11, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 11, 2026

C4 Therapeutics reports updated cemsidomide data at EHA 2026 - grafa.com

Jun 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - Investing News Network

Jun 11, 2026

C4 Therapeutics presents cemsidomide data at EHA congress - Investing.com UK

Jun 11, 2026

C4 Therapeutics presents cemsidomide data at EHA congress By Investing.com - Investing.com Australia

Jun 11, 2026

C4 Therapeutics (CCCC) Unveils Phase 1 Trial Insights on Cemsido - GuruFocus

Jun 11, 2026

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D - marketscreener.com

Jun 11, 2026

C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress - TipRanks

Jun 11, 2026

C4 Therapeutics posts Phase 1 cemsidomide data and corporate presentation ahead of EHA 2026 - TradingView

Jun 11, 2026

C4 Therapeutics (NASDAQ: CCCC) highlights cemsidomide Phase 1 response rates in RRMM - Stock Titan

Jun 11, 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population - The Manila Times

Jun 11, 2026

Heavily pretreated myeloma patients see durable responses on C4 oral therapy - Stock Titan

Jun 11, 2026

Jun 09, 2026

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 09, 2026

Jun 05, 2026

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record

Jun 05, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Jun 05, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 05, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jun 05, 2026

Jun 04, 2026

Director Anderson (NASDAQ: CCCC) exercises 1,070 options at $2.11 - Stock Titan

Jun 04, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 04, 2026

Abeona Therapeutics (ABEO) details FDA Pre-IND meeting and 2027 IND goal for ABO-701 - Stock Titan

Jun 04, 2026

Jun 03, 2026

Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options - Stock Titan

Jun 03, 2026

Viking Therapeutics (NASDAQ: VKTX) Chief Medical Officer named insider in Form 3 filing - Stock Titan

Jun 03, 2026

Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat - Traders Union

Jun 03, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2026

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Yahoo Finance

Jun 03, 2026